Brokerages Set Invivyd, Inc. (NASDAQ:IVVD) PT at $8.00

Shares of Invivyd, Inc. (NASDAQ:IVVD) have received an average recommendation of “Hold” from the six research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.00.

IVVD has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research report on Thursday, February 26th.

Insiders Place Their Bets

In other Invivyd news, insider Jill Andersen sold 34,939 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $55,203.62. Following the transaction, the insider owned 181,736 shares of the company’s stock, valued at $287,142.88. The trade was a 16.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO William E. Duke sold 20,964 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the chief financial officer directly owned 107,717 shares in the company, valued at $170,192.86. This trade represents a 16.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 227,172 shares of company stock worth $354,534 in the last 90 days. Company insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IVVD. Courier Capital LLC acquired a new position in shares of Invivyd during the 4th quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. acquired a new position in shares of Invivyd during the 4th quarter worth approximately $27,000. DRW Securities LLC acquired a new position in shares of Invivyd during the 4th quarter worth approximately $27,000. ProShare Advisors LLC acquired a new position in shares of Invivyd during the 4th quarter worth approximately $30,000. Finally, State of Wyoming acquired a new position in shares of Invivyd during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Stock Performance

Shares of Invivyd stock opened at $1.46 on Friday. The business’s 50 day simple moving average is $1.58 and its 200 day simple moving average is $1.94. Invivyd has a 52-week low of $0.48 and a 52-week high of $3.07. The firm has a market cap of $412.89 million, a PE ratio of -4.56 and a beta of 0.73.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.